Bisleri-S Iv Injection 100Mg/5Ml (1 Box = 5 Ampoules)

Name: Bisleri-S Iv Injection 100Mg/5Ml (1 Box = 5 Ampoules)
Brand: SAMI PHARM (PVT) LTD.
Price: 1971.25

Brand : sami pharm (pvt) ltd.

Rs. 1,971.25

Rs. 2,075.00

|

QUICK DELIVERY

Bisleri-S Iv Specification

Requires Prescription (YES/NO)

Yes

Generics

Iron sucrose

Used For

Fluids & Electrolytes

How it works

Iron sucrose injection is in a class of medications called iron replacement products. It works by replenishing iron stores so that the body can make more red blood cells.

Bisleri-S Iv Usage And Safety

Dosage

Iron sucrose

Side Effects

Common: transient taste perversions (in particular metallic taste). Uncommon: headache, dizziness, hypotension and collapse, tachycardia, palpitations, bronchospasm, dyspnea, nausea, vomiting, abdominal pain, diarrhea pruritus, urticaria, rash, exanthema, erythema, muscle cramps, myalgia, fever, shivering, flushing, chest pain and tightness. Injection site disorders such as superficial phlebitis, burning, swelling. Rare: paresthesia, anaphylactoid reactions (rarely involving arthralgia), peripheral edema, fatigue, asthenia, malaise. Isolated cases: reduced level of consciousness, light-headed feeling, confusion, angioedema, swelling of joints, hyperhidrosis and back pain. Hemodialyis dependent-chronic kidney disease (HDD-CKD) patients: hypotension, muscle cramps, nausea, headache, graft complications, vomiting, dizziness, hypertension, chest pain and diarrhea. Non-dialysis dependent-chronic kidney disease (NDD-CKD) patients: dysgeusia, peripheral edema, diarrhea, constipation, nausea, dizziness and hypertension . Patients receiving erythropoietin may experience: diarrhea, edema, nausea, vomiting, arthralgia, back pain, headache, hypertension, dysgeusia, dizziness, extremity pain and injection site burning. Peritoneal dialysis dependent-chronic kidney disease (PDD-CKD) patients: diarrhea, peritoneal infection, vomiting, hypertension, pharyngitis, peripheral edema and nausea.

Drug Interactions

As with all parenteral iron preparations, iron sucrose should not be administered concomitantly with oral iron preparations since the absorption of oral iron is reduced. Therefore, oral iron therapy should be started at least 5 days after the last injection of Iron Sucrose.

Indication

Iron sucrose is indicated for the treatment of iron deficiency in the following: - Where there is a clinical need to deliver iron rapidly to iron stores. - Patients who cannot tolerate oral iron therapy or who are noncompliant. - In active inflammatory bowel disease where oral iron preparations are ineffective. - Non-dialysis dependent-chronic kidney disease (NDD-CKD) patients receiving an erythropoietin. - Non-dialysis dependent-chronic kidney disease (NDD-CKD) patients not receiving an erythropoietin. - Hemodialysis dependent-chronic kidney disease (HDD-CKD) patients receiving an erythropoietin. - Peritoneal dialysis dependent-chronic kidney disease (HDD-CKD) patients receiving an erythropoietin

When not to Use

The use of iron sucrose is contra-indicated in cases of: - Known hypersensitivity to iron sucrose or any of its components. - Anemias not attributable to iron deficiency. - Iron overload or disturbances in utilization of iron. - Patients with a history of asthma, eczema or other atopic allergy, because they are more susceptible to experience allergic reactions. - Pregnancy first trimester .

Bisleri-S Iv Precautions

Precaution

Parenteral administered iron preparations can cause allergic or anaphylactoid reactions, which may be potentially fatal. Therefore, treatment for serious allergic reactions and facilities with the established cardio-pulmonary resuscitation procedures should be available.

Bisleri-S Iv Warnings

Warning 1

In patients with liver dysfunction, parenteral iron should only be administered after careful risk/benefit assessment. Parenteral iron administration should be avoided in patients with hepatic dysfunction where iron overload is a precipitating factor, in particular Porphyria Cutanea Tarda (PCT). Careful monitoring of iron status is recommended to avoid iron overload .

Warning 2

Parenteral iron must be used with caution in case of acute or chronic infection. It is recommended that the administration of iron sucrose is stopped in patients with ongoing bacteremia. In patients with chronic infection a risk/benefit evaluation has to be performed, taking into account the suppression of erythropoiesis .

Warning 3

Hypotensive episodes may occur if the injection is administered too rapidly. Allergic reactions, sometimes involving arthralgia, have been more commonly observed when the recommended dose is exceeded .

Download the Dvago App